NIH PAR · NIDDK · R21
PAR-25-068: Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This Notice of Funding Opportunity (NOFO) invites applications for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently outlined by the NIH Office of AIDS Research (OAR) in NOT-20-018, UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding, scientific priorities. Potential topics could address multiple overarching priorities. These include elucidation of unique pathophysiological mechanisms contributing to HIV comorbidities, coinfections, and complications (CCCs) affecting organs, tissues, and processes within the mission of the…
- NOFO number
- PAR-25-068
- Type
- PAR
- Activity code
- R21
- Primary institute
- NIDDK · National Institute of Diabetes and Digestive and Kidney Diseases
- Clinical trials
- Optional
- Posted
- Jan 8, 2025
- Opens
- Apr 7, 2025
- Expires
- Nov 17, 2027
PAR-25-068 due dates
4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| Not Applicable | Not Applicable | May 07, 2025 * | July 2025 | October 2025 | December 2025 |
| Not Applicable | Not Applicable | September 07, 2025 | November 2025 | January 2026 | April 2026 |
| Not Applicable | Not Applicable | January 07, 2026 * | March 2026 | May 2026 | July 2026 |
| Not Applicable | Not Applicable | May 07, 2026 * | July 2026 | October 2026 | December 2026 |
| June 16, 2026 * | July 16, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 16, 2026 * | November 16, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 16, 2027 | March 16, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 16, 2027 * | July 16, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 16, 2027 * | November 16, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-068
NIH RePORTER lists 1 project funded under PAR-25-068 in FY2022–FY2026, with $240K in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
1
Distinct projects, FY2022–FY2026
New awards
1
Type 1 (new project) award records
NIH funding
$240K
Award dollars under PAR-25-068, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 1 | 1 | $240K |
Institutions with the most funding
- Baylor College of Medicine$240K · 1 project
Funding institutes
- NIDDK$240K · 1
Activity codes funded
- R211 record
Most recent new awards
- Mouse models for metabolic co-morbidities in persons living with HIV (opens NIH RePORTER)
Baylor College of Medicine · 1R21DK146753-01A1 · NIDDK · Notice Aug 27, 2026
$240KR21
What its predecessor PAR-24-162 funded
PAR-25-068 reissues PAR-24-162. Its funding history is the best guide to who wins under this program: 2 projects and $881K in FY2022–FY2026.
Projects funded
2
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$881K
Award dollars under PAR-24-162, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 2 | 2 | $881K |
| FY2026 | 0 | 0 | $0 |
Institutions with the most funding
- University of California, San Francisco$451K · 1 project
- Emory University$430K · 1 project
Funding institutes
- NIDDK$881K · 2
Activity codes funded
- R212 records
Most recent new awards
- Utilizing the ex vivo rectal explant challenge model to evaluate HIV-1 Transmitted/Founder replication and inflammation within human gut mucosal tissue (opens NIH RePORTER)
Emory University · 1R21DK142595-01A1 · NIDDK · Notice Sep 18, 2025
$430KR21
- Investigation of the Role of MicroRNAs in Adipose Tissue from People Infected with HIV Who Develop Type 2 Diabetes (opens NIH RePORTER)
University of California, San Francisco · 1R21DK145238-01 · NIDDK · Notice Sep 4, 2025
$451KR21
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-068. Contact the program officer at the institute that fits your research before applying.
- NIDDK · National Institute of Diabetes and Digestive and Kidney Diseases
- none
Related notices
Jan 28, 2026 · NOT-OD-26-029
NIH Removing AIDS Application Due Dates from NOFOs.
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Notices of Special Interest (NOSIs)
NIH has attached 1 NOSI to PAR-25-068; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- The combined budget for direct costs for the two-year project period may not exceed 275,000. No more than 200,000 may be requested in any single year.
- Project period
- The total project period may not exceed 2 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-162.
Other open NOFOs for R21
- PAR-25-357NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)NEI · next due Oct 16, 2026
- PA-25-304NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)NIH · next due Oct 16, 2026
- PA-25-306NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)NIH · next due Oct 16, 2026
- PAR-25-346Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)NCI · next due Oct 16, 2026
- PAR-25-321Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)NCI · next due Oct 16, 2026
- PAR-25-266Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)NICHD · next due Oct 16, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.